Loading organizations...
§ Private Profile · Évry, Ile-de-France, France
French biopharmaceutical company developing immunotherapies for HIV infection and cancer, with VAC-3S therapeutic vaccine completing Phase I/IIa.
InnaVirVax is a French biopharmaceutical company based in Évry, Île-de-France, primarily focused on developing innovative immunotherapies for HIV infection and cancer. Its lead program, VAC-3S, is a therapeutic vaccine specifically designed to complement antiretroviral drugs for HIV, having successfully completed Phase I/IIa clinical trials demonstrating safety and tolerability. The company has secured $4.9 million in Series B funding from private equity and family offices, with its HIV therapy projected to achieve peak annual sales exceeding €1 billion. Operating with a team of approximately 4-10 employees, InnaVirVax anticipates reaching an annual revenue of $7 million by 2025. Co-founded in March 2008 by Joël Crouzet, PhD, who also serves as CEO, the firm continues to advance its therapeutic pipeline.
InnaVirVax has raised $8.8M across 2 funding rounds.
InnaVirVax has raised $8.8M in total across 2 funding rounds.
InnaVirVax has raised $8.8M in total across 2 funding rounds.
InnaVirVax's investors include Fa Di e, G1J Ile-de-France, Catherine Boule, Paris Region Venture Fund, Christian Pradeyrol, Fa Diese, Pradeyrol Développement, CapDecisif 2.
InnaVirVax has raised $8.8M across 2 funding rounds. Most recently, it raised $3.9M Other Equity in July 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 17, 2015 | $3.9M Venture Round | — | FA DI E, G1J ILE DE France, Catherine Boule, Paris Region Venture Fund, Christian Pradeyrol | Announced |
| Feb 14, 2012 | $4.9M Series B | FA Diese, Paris Region Venture Fund, Pradeyrol Développement | CapDecisif 2, G1J ILE DE France | Announced |